跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IMFINZI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
IMFINZI
Authorized
STANDARD
IMFINZI
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
164182fcb9af3f65
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
164182fcb9af3f65
Drug Approval Canada Name
IMFINZI
Product Name
IMFINZI
Status
Marketed
Status Date
2017-11-20
Original Market Date
2017-11-20
Din
02468816
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FF03 DURVALUMAB
Atc Name
l 01 ff 03
Aig Number
0159570001
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
DURVALUMAB
50 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
164182fcb9af3f65
Type
Standard
Back to Health Canada Approvals